Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Retirement planning is essential for achieving financial stability in your later years. Learn why it's never too early to start planning.
21,478 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A quick online search turned into a costly lesson when a creator clicked the first balance-check link for a Sephora g...
As the Fed hints at slower rate moves, crypto markets stir. This guide explains what the federal reserve signals good...
Two AI-focused names have pulled back recently, but their paths diverge. This guide breaks down why palantir sandisk ...
Sweetgreen stock surged today as growth signals and strategic moves raised investor confidence. This guide breaks dow...
AI chips are reshaping tech, and ARM Holdings could ride the wave as a major royalty player. This article explains wh...
On July 22, AI-driven hardware names moved the dial as SMCI posted a surprising margin beat and a burst of orders. Th...
New reports say Lagarde is weighing an earlier departure, which could derail the ECB's digital euro plan and MiCA rol...
Bill Gates’ foundation says a sudden withdrawal from a major AI summit was a move to keep the focus squarely on the e...
Winter demand and a growing data-center footprint push grid strain. The Trump administration accelerates a coal reviv...
No stock goes straight up, and Walmart’s latest report is a perfect example. Strong e-commerce gains meet a cautious ...
XRP is facing renewed selling pressure across major trading pairs, with a looming test of the $1.20 support and criti...